Cargando…

Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer

Metastatic triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. Combination of systemic chemotherapy and immune checkpoint blockade is effective but of limited benefit due to insufficient intratumoral infiltration of cytotoxic T lymphocytes (CTLs) and the accumulation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Chao, Zhang, Wen, Wang, Jinming, Zhai, Yihui, Xiong, Fengqin, Cai, Ying, Gong, Xiang, Zhu, Binyu, Zhu, Helen He, Wang, Hao, Li, Yaping, Zhang, Pengcheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513558/ https://www.ncbi.nlm.nih.gov/pubmed/36176911 http://dx.doi.org/10.1016/j.apsb.2022.02.021

Ejemplares similares

Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice
por: Daei Farshchi Adli, Amir, et al.
Publicado: (2021)

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
por: Milanović, Dušan, et al.
Publicado: (2012)

Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid
por: Zhang, Shi-Jie, et al.
Publicado: (2010)

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
por: Chen, Yichao, et al.
Publicado: (2016)

In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy
por: Li, Jiehan, et al.
Publicado: (2022)

Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice
por: He, Hongliang, et al.
Publicado: (2020)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression
por: Jia, Wenxiao, et al.
Publicado: (2021)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors
por: Zhang, Chun-ge, et al.
Publicado: (2014)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
por: Huang, Dongmei, et al.
Publicado: (2022)

Synthesis and Properties of α-Mangostin and Vadimezan Conjugates with Glucoheptoamidated and Biotinylated 3rd Generation Poly(amidoamine) Dendrimer, and Conjugation Effect on Their Anticancer and Anti-Nematode Activities
por: Markowicz, Joanna, et al.
Publicado: (2022)

Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin
por: Yuan, Yue, et al.
Publicado: (2016)

A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy
por: Zhu, Yuan-Xue, et al.
Publicado: (2022)

Serum high-density lipoprotein level and prognosis of ovarian cancer
por: Hongyan, Jiang, et al.
Publicado: (2023)

Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy
por: Gong, Miaomiao, et al.
Publicado: (2019)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy
por: Lang, Tianqun, et al.
Publicado: (2023)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia
por: McMahon, Kaylin M., et al.
Publicado: (2017)

Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases
por: Schultz, Mark L., et al.
Publicado: (2019)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
por: Zhai, Wen-Yu, et al.
Publicado: (2023)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease
por: Roatt, Bruno Mendes, et al.
Publicado: (2014)

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer
por: Facciotto, Chiara, et al.
Publicado: (2019)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
por: Zhu, Yun, et al.
Publicado: (2021)

A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles
por: Zuo, Huaqin, et al.
Publicado: (2022)

Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
por: Liao, Jiatao, et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy
por: Wang, Jie, et al.
Publicado: (2019)

Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma
por: Kuai, Rui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3ba1orcvp7t2n4vh1vd8m6m52d